Worsening UK Pharma Sector Close To ‘Tipping Point,’ Warns GSK Chief
UK Falling Behind On Trials, Medicines Uptake And Regulation
Executive Summary
Dame Emma Walmsley has delivered a broadside to the UK government, urging it to reverse a raised revenues ‘clawback’ for pharma companies and boost new medicines uptake in order to maintain the UK’s competitiveness in life sciences.
You may also be interested in...
Bayer May Not Launch In Innovation-Unfriendly European Markets
The attractiveness of investing in R&D and launching new products in Europe is wearing off, especially when compared with the US marketplace, Bayer pharma head Stefan Oelrich tells Scrip.
UK Launches Inquiry Into Its Clinical Trials Problems After Pharma Outcry
Stung by criticism from the AstraZeneca and GSK CEOs, the UK government has launched an independent review into commercial clinical trials in the hopes of reversing a steep decline.
UK Launches Inquiry Into Its Clinical Trials Problems After Pharma Outcry
Stung by criticism from the AstraZeneca and GSK CEOs, the UK government has launched an independent review into clinical trials in the hopes of reversing a steep decline.